Heartflow, Inc. $HTFL Shares Bought by Summit Partners Public Asset Management LLC

Summit Partners Public Asset Management LLC raised its position in Heartflow, Inc. (NASDAQ:HTFL) by 48.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,259,121 shares of the company’s stock after acquiring an additional 410,659 shares during the quarter. Summit Partners Public Asset Management LLC’s holdings in Heartflow were worth $36,703,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $27,000. Legal & General Group Plc acquired a new stake in shares of Heartflow in the third quarter valued at approximately $59,000. Strs Ohio acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $99,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $131,000. Finally, Staley Capital Advisers Inc. acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $204,000.

Heartflow Price Performance

NASDAQ HTFL opened at $32.05 on Wednesday. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The firm has a market capitalization of $2.76 billion and a PE ratio of -10.31. The company’s 50 day simple moving average is $29.60 and its 200 day simple moving average is $28.33.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million for the quarter. The company’s revenue for the quarter was up 41.3% on a year-over-year basis. Sell-side analysts anticipate that Heartflow, Inc. will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. William Blair assumed coverage on shares of Heartflow in a report on Monday, May 4th. They issued an “outperform” rating for the company. Canaccord Genuity Group reduced their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a report on Friday, May 15th. JPMorgan Chase & Co. reduced their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Wells Fargo & Company raised their price objective on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Heartflow in a research note on Thursday, June 11th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Heartflow currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Insider Activity at Heartflow

In other Heartflow news, insider Campbell Rogers sold 64,533 shares of Heartflow stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $24.64, for a total value of $1,590,093.12. Following the transaction, the insider owned 81,002 shares in the company, valued at approximately $1,995,889.28. The trade was a 44.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $29.23, for a total transaction of $27,732,167.11. Following the completion of the transaction, the insider owned 8,448,158 shares in the company, valued at approximately $246,939,658.34. This trade represents a 10.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 2,205,971 shares of company stock worth $64,308,951 over the last quarter. 7.70% of the stock is currently owned by company insiders.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.